Legislature(2025 - 2026)BUTROVICH 205
04/15/2025 03:30 PM Senate HEALTH & SOCIAL SERVICES
Note: the audio ![]()
and video ![]()
recordings are distinct records and are obtained from different sources. As such there may be key differences between the two. The audio recordings are captured by our records offices as the official record of the meeting and will have more accurate timestamps. Use the icons to switch between them.
| Audio | Topic |
|---|---|
| Start | |
| SB147 | |
| SB134 | |
| Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
| *+ | SB 147 | TELECONFERENCED | |
| += | SB 134 | TELECONFERENCED | |
ALASKA STATE LEGISLATURE
SENATE HEALTH AND SOCIAL SERVICES STANDING COMMITTEE
April 15, 2025
3:30 p.m.
MEMBERS PRESENT
Senator Forrest Dunbar, Chair
Senator Cathy Giessel, Vice Chair
Senator Matt Claman
Senator Löki Tobin
Senator Shelley Hughes
MEMBERS ABSENT
All members present
COMMITTEE CALENDAR
SENATE BILL NO. 147
"An Act relating to the prescription and administration of drugs
and devices by pharmacists; relating to reciprocity for
pharmacists; and providing for an effective date."
- HEARD & HELD
SENATE BILL NO. 134
"An Act relating to pharmacy benefits managers; relating to
third-party administrators; and providing for an effective
date."
- MOVED SB 134 OUT OF COMMITTEE
PREVIOUS COMMITTEE ACTION
BILL: SB 147
SHORT TITLE: PHARMACIST PRESCRIPTION AUTHORITY
SPONSOR(s): SENATOR(s) GIESSEL BY REQUEST
03/26/25 (S) READ THE FIRST TIME - REFERRALS
03/26/25 (S) HSS, L&C
04/15/25 (S) HSS AT 3:30 PM BUTROVICH 205
BILL: SB 134
SHORT TITLE: PHARMACY BENEFITS MANAGER;3RD PARTY ADMIN
SPONSOR(s): SENATOR(s) GIESSEL
03/18/25 (S) READ THE FIRST TIME - REFERRALS
03/18/25 (S) HSS, L&C
04/01/25 (S) HSS AT 3:30 PM BUTROVICH 205
04/01/25 (S) Heard & Held
04/01/25 (S) MINUTE(HSS)
04/03/25 (S) HSS AT 3:30 PM BUTROVICH 205
04/03/25 (S) Heard & Held
04/03/25 (S) MINUTE(HSS)
04/15/25 (S) HSS AT 3:30 PM BUTROVICH 205
WITNESS REGISTER
JANE CONWAY, Staff
Senator Cathy Giessel
Alaska State Legislature
Juneau, Alaska
POSITION STATEMENT: Provided the sectional analysis for SB 147.
ASHLEY SCHABER, Chair
Alaska Board of Pharmacy
Anchorage, Alaska
POSITION STATEMENT: Testified by invitation on SB 147.
BRANDY SEIGNNEMARTIN, Executive Director
Alaska Pharmacists Association
Anchorage, Alaska
POSITION STATEMENT: Testified by invitation on SB 147.
JENNIFER ADAMS, Associate Dean
L.S. Skaggs College of Pharmacy
Idaho State University/University of Alaska Anchorage
Pocatello, Idaho
POSITION STATEMENT: Testified by invitation on SB 147.
SYLVAN ROBB, Director
Division of Corporations, Business,
and Professional Licensing
Department of Commerce, Community
and Economic Development (DCCED)
Juneau, Alaska
POSITION STATEMENT: Answered questions regarding SB 147.
ACTION NARRATIVE
3:30:34 PM
CHAIR DUNBAR called the Senate Health and Social Services
Standing Committee meeting to order at 3:30 p.m. Present at the
call to order were Senators Giessel, Hughes, Claman, Tobin, and
Chair Dunbar.
SB 147-PHARMACIST PRESCRIPTION AUTHORITY
3:31:14 PM
CHAIR DUNBAR announced the consideration of SENATE BILL NO. 147
"An Act relating to the prescription and administration of drugs
and devices by pharmacists; relating to reciprocity for
pharmacists; and providing for an effective date."
3:31:34 PM
SENATOR GIESSEL speaking as sponsor of SB 147 introduced the
bill. SB 147 grants pharmacists prescription authority and
clarifies prior legislation to allow independent prescribing
within their education, training, and experience. Developed in
collaboration with the Alaska Board of Pharmacy and the Alaska
Pharmacy Association, SB 147 aligns with existing state
standards of care and federal models, including the PREP and MAT
Acts. She said the bill addresses Alaska's limited healthcare
capacity, particularly in rural areas, by enabling pharmacists
to provide direct care for minor conditions such as flu, strep,
COVID-19, urinary tract infections, and similar ailments.
Pharmacists are highly trained, hold Doctor of Pharmacy degrees,
and are already regulated to ensure patient safety. She said
evidence from other states shows pharmacist-provided care
improves access, maintains quality, and reduces costs.
Approximately 90 percent of Americans live within five miles of
a community pharmacy.
3:37:12 PM
SENATOR GIESSEL stated that the study indicates that not all
pharmacist-initiated treatments require testing and that many
minor ailments may be effectively treated in community
pharmacies based on patient-reported symptoms and examination.
She said uncomplicated urinary tract infections are a common
example, with evidence showing pharmacists demonstrate strong
antimicrobial stewardship and appropriate antibiotic use.
Results from a three-year study showed 977 patients used these
services, with care outcomes comparable to emergency rooms,
primary care, and urgent care settings. The analysis found
significantly lower costs for pharmacist-provided care,
excellent follow-up, and estimated savings of approximately
$23.5 million, demonstrating the effectiveness and cost-
efficiency of pharmacy-based healthcare services.
3:41:24 PM
JANE CONWAY, Staff, Senator Cathy Giessel, Alaska State
Legislature, Juneau, Alaska, provided the sectional analysis for
SB 147.
[Original punctuation provided.]
Pharmacist Prescription Authority
Sectional Analysis
"An Act relating to the prescription and
administration of drugs and devices by pharmacists;
relating to reciprocity for pharmacists; and providing
for an effective date."
Section 1. Amends AS 08.80.030(b) Powers and duties of
the board.
to require that a licensed pharmacist who prescribes,
administers, or dispenses a controlled substance under
state law or federal law to a person in the state
register with the controlled substance prescription
database (PDMP).
Section 2. Amends AS 08.80.110 Qualifications for
licensure by examination.
to require that a pharmacist who holds a Drug
Enforcement Agency (DEA) number applying for licensure
(via examination) receive education in pain management
and opioid use and addiction, in alignment with other
practitioners in Alaska who hold DEA numbers.
Section 3. Amends AS 08.80.145 Reciprocity; license
transfer.
to require that a pharmacist who holds a DEA number
applying for licensure (via reciprocity) receive
education in pain management and opioid use and
addiction, in alignment with other practitioners in
Alaska who hold DEA numbers and pay the associated
fees.
Section 4. Amends AS 08.80.165 Continuing education
requirements.
to require a pharmacist who holds a DEA number and
renews licensure in Alaska meet continuing education
requirements including at least two hours of education
in pain management and opioid use and addiction in the
two years preceding license renewal, in alignment with
other practitioners in Alaska who hold DEA numbers. A
pharmacist whose practice does not include pain
management and opioid prescription, or administration
is exempt from this requirement.
Section 5. Amends AS 08.80.337 Other patient care
services.
(a)to clarify that a pharmacist may not provide
patient care services under a collaborative agreement
with another pharmacist. [email protected]
Section 6. Amends AS 08.80.337 Other patient care
services.
(d) to clarify that "patient care services" mean
medical care services that include the prescription or
administration of a drug or device to a patient for
the purposes of curing or preventing a disease,
reduction of patient symptoms or for slowing the
disease progression.
Section 7. Amends and adds a new subsection to AS
08.80.337 Other patient care services.
(e) requiring that a pharmacist prescribing or
administering a drug or device under this section
recognize the limits of the pharmacist's education,
training, and experience and consult with and refer to
other practitioners as appropriate. This aligns with
standard of care and pharmacy regulation.
Section 8. Amends AS 08.80.480 Definitions.
(30) to clarify that the "practice of pharmacy"
includes providing patient care services in accordance
with AS 08.80.337. This includes patient care services
provided independently or under collaborative
practice.
Section 9. Amends and adds a new paragraph to AS
08.80.480 Definitions.
(40) adds to the definition of opioid to include opium
and opiate substances and opium and opiate derivatives
Section 10. Repeals AS 08.80.337 Other patient care
services (c)
to align with clarifications in Section 6.
Section 11. Provides for an effective date of January
1, 2026.
MS. CONWAY noted that Section 9 was added to comply with the DA
requirement and Section 10 has an error.
3:46:08 PM
ASHLEY SCHABER, Chair, Alaska Board of Pharmacy, Anchorage,
Alaska, testified by invitation on SB 147. She moved to slide 2,
2024 Strategic Plan, and stated that the 2024 Alaska Board of
Pharmacy Strategic Plan guides all board decisions on statutes
and regulations. SB 147 aligns with the plan's fourth goal,
"grow the economy while promoting economic growth, community
health, and safety."
3:47:01 PM
MS. SCHABER moved to slide 3, Background of SB 147, and
discussed the following:
[Original punctuation provided.]
-Result of multi-year, multi-chair Board of Pharmacy
review of statutes and regulations to align Alaska
pharmacists' license authority with their education,
training, and experience to increase access to care.
-HB 145 (2021-2022)
-New statute added for "other patient care
services"
-Clarifications needed
-SB 147 addresses changes by:
-Increasing access to care
-Incorporating established models of care
-Encouraging interdisciplinary engagement
-Collaborative effort between the Alaska Board of
Pharmacy and the Alaska Pharmacy Association
3:48:12 PM
MS. SCHABER moved to slide 4, Safe Access with Interdisciplinary
Engagement, and stated that SB 147 expands access to pharmacist-
provided patient care services while aligning state statutes
with pharmacists' education and training. The bill also promotes
interdisciplinary collaboration by requiring pharmacists to
recognize the limits of their scope and to consult with or refer
patients to other healthcare practitioners when appropriate.
3:48:53 PM
MS. SCHABER moved to slide 5, Incorporates Established Models of
Care, and stated that SB 147 grants Alaska pharmacists'
statutory authority to use proven models of care under a
standard-of-care regulatory framework. This approach aligns
pharmacy regulation with other health professions, supports
practice within training and scope, enhances patient safety, and
is consistent with recent federal legislation and established
models such as those used by the Veterans Health Administration.
3:49:58 PM
MS. SCHABER moved to slide 6, Support, and asked the committee
for support of SB 147.
3:50:20 PM
SENATOR CLAMAN asked how a pharmacist could respond if a patient
requested an opioid prescription for pain management.
3:50:45 PM
MS. SCHABER replied that the definition of opioid is included to
reflect required pharmacist training. She said the established
model authorizes pharmacists to provide medications for opioid
use disorder, not to prescribe opioids for pain treatment.
3:51:20 PM
SENATOR CLAMAN asked whether a pharmacist, visited by a person
with a long history of pain complaints, would be expected to
tell that person to go see their regular medical provider .
3:51:40 PM
MS. SCHABER replied, yes.
3:51:42 PM
SENATOR CLAMAN explained that he has a friend with a lung
infection that has gone through a couple types of medications.
He asked whether his friend could see a pharmacist to get the
drug or would the friend need to go to a doctor.
3:52:42 PM
MS. SCHABER answered that it would be considered a complex case
requiring consultation with an infectious disease specialist.
Such a case is an example of when a pharmacist is expected to
engage in interdisciplinary collaboration.
3:53:03 PM
SENATOR TOBIN asked for an explanation of the different
scheduled drugs list in SB 147, page 2.
MS. SCHABER replied that the Drug Enforcement Agency (DEA)
establishes different levels of controlled substances, known as
schedules, to regulate medications based on the potential for
abuse and addiction. The numbers referenced on page 2 correspond
to the DEA-controlled schedules, indicating the relative risk
and regulatory requirements associated with each medication.
3:53:59 PM
CHAIR TOBIN asked whether she could describe the scope and types
of substances.
3:54:22 PM
MS. SCHABER said under the test-to-treat model allowed by this
legislation, commonly prescribed medications could include
antivirals, while medications for opioid use disorder would
likely fall under Schedule III for medication-assisted therapy.
3:55:02 PM
CHAIR DUNBAR said SB 147, Section 8, expands the definition of
pharmacy practice to include patient care services. He asked
what would occur if a pharmacist chose not to offer these
services and whether the new definition of pharmacy practice
would require them to complete additional training.
3:55:47 PM
MS. SCHABER replied that SB 147 does not require a pharmacist
licensee in the state to provide these services. The decision is
left to the pharmacist or pharmacy, as the bill authorizes but
does not mandate participation.
CHAIR DUNBAR asked if additional educational requirements are
also voluntary.
3:56:59 PM
MS. SCHABER replied that the continuing education changes in SB
147 apply only to pharmacists who prescribe medication-assisted
therapy for opioid use disorder and hold a DEA registration. All
other pharmacists would continue being subject to the existing
requirement of 30 hours of continuing education every two years.
She added that unless the Board determines through regulation
that continuing education requirements should change.
3:57:45 PM
SENATOR HUGHES expressed concern that diagnosis and treatment
typically rely on physical examinations, and that SB 147 appears
broader than originally intended. She asked why the bill is not
more narrowly defined and whether similarly broad authority
exists in other states.
3:58:56 PM
MS. SCHABER replied that there are other states that do have
this broad prescriptive authority. She said there are protocols
in place to help guide the pharmacist.
3:59:55 PM
SENATOR HUGHES asked whether the board would establish
regulations specifying which services pharmacists may provide
and when referrals to other providers are required.
4:00:33 PM
MS. SCHABER replied that the Board anticipates promulgating
regulations under SB 147 and would continue to rely on existing
standards of care and practice. Rather than adopting rigid
lists, the Board expects to maintain a flexible standard-of-care
regulatory approach that can evolve with changes in pharmacy
practice and clinical guidelines.
4:01:36 PM
BRANDY SEIGNNEMARTIN, Executive Director, Alaska Pharmacists
Association, Anchorage, Alaska, testified by invitation on SB
147. She stated that the Alaska Pharmacy Association represents
pharmacists, student pharmacists, and pharmacy technicians
statewide and supports high-quality pharmacy care in local
communities. Pharmacists in Alaska practice across community
pharmacies, tribal health systems, hospitals, clinics, long-term
care, and public health settings, providing immunizations,
health screenings, medication management, patient counseling,
and prevention of medication-related complications. She said SB
147 builds on this foundation by allowing pharmacists to provide
limited patient care services, including prescribing, within
their education, training, and experience. These roles are not
new and have been safely implemented for decades in federal
systems such as the Indian Health Service and the Veterans
Health Administration. She said SB 147 uses a standard-of-care
regulatory model, requires interdisciplinary collaboration and
referrals for complex cases, and relies on evidence-based
guidelines. By aligning statute with pharmacists' training, SB
147 improves access to safe, timely care, particularly in rural
and underserved communities, reduces strain on the healthcare
system, and helps address workforce burnout while maintaining
strong patient safety safeguards.
4:06:59 PM
MS. SEIGNNEMARTIN stated that SB 147 would allow pharmacists to
provide test-and-treat services for minor illnesses, preventive
services such as smoking cessation and HIV prevention, treatment
for minor ailments, support for medication-assisted therapy for
opioid use disorder, and collaborative management of chronic
conditions. These evidence-based models, already used in other
states and federal systems, improve efficiency by utilizing
healthcare team members at the appropriate level of care. She
noted that studies show pharmacist-provided care increases
access while reducing costs, with an estimated $4.81 return for
every $1 invested and $277 lower cost per episode for minor
illness care without compromising outcomes. SB 147 adds capacity
to Alaska's strained healthcare system, improves access,
especially for working patients and rural communities, maintains
patient safety through standard-of-care safeguards, and
represents a practical, cost-effective solution to key
healthcare challenges.
4:10:04 PM
SENATOR TOBIN noted she was going to ask about disaster response
and the role of Indian Health Services in protecting communities
but acknowledged that it was already addressed thoroughly. She
asked for an overview of pharmacists' licensure requirements,
continuing education obligations, and the education and training
necessary to earn a pharmacy degree.
4:10:38 PM
MS. SEIGNNEMARTIN answered that to earn a Doctor of Pharmacy
(PharmD) degree, students first complete at least three years of
undergraduate coursework to meet program prerequisites, though
many students also earn a bachelor's degree before entering
pharmacy school. The pharmacy program itself is an intensive
four-year curriculum. She said during the first three years,
students primarily engage in didactic, classroom-based learning,
attending lectures and laboratory sessions five days a week for
approximately 32 weeks each year. From the very beginning,
students also participate in hands-on patient care experiences,
volunteering in community settings and gaining practical
exposure to pharmacy practice. Between the first and second
years, they complete introductory pharmacy practice experiences,
starting their clinical rotations early. She said in the final
year, students dedicate themselves entirely to clinical
training, completing seven six-week rotations in a variety of
practice settings, which together provide more than 1,740 hours
of supervised patient care. This extensive training exceeds that
of many other healthcare professions, ensuring graduates are
well-prepared to provide safe, competent care. She said in
addition to completing the degree, graduates must pass the North
American Pharmacy Licensure Examination (NAPLEX), which serves
as the minimum competency standard required to obtain licensure
and practice as a pharmacist in any state. This rigorous
combination of education, practical experience, and licensure
ensures that pharmacists are highly trained and capable
healthcare professionals.
4:12:50 PM
CHAIR TOBIN asked for more oversight of the Board of Pharmacy
and if there is a bad actor what is the consequences for their
actions.
4:12:58 PM
MS. SEIGNNEMARTIN replied that pharmacists are closely monitored
by the Board of Pharmacy. She said the Board investigates
complaints, ensures regulatory compliance, and holds licensees
accountable for any patient harm or misconduct.
4:13:35 PM
SENATOR HUGHES expressed concern that while pharmacist-provided
care can improve access and convenience, patients with chronic
conditions like diabetes or hypertension might bypass their
regular physicians, potentially weakening in-person
relationships and the opportunity for physical exams. She
emphasized the importance of pharmacists referring patients to
appropriate practitioners when needed. She asked if the patient
would be referred back to their doctor to get the prescription.
4:15:03 PM
MS. SEIGNNEMARTIN replied that maintaining a relationship with a
primary care provider is crucial. SB 147 supports a standard-of-
care, team-based model. Pharmacists can provide urgent or
routine care, such as insulin refills or chronic disease
management, while coordinating with the patient's primary care
provider, often working alongside them in clinics to monitor
conditions like diabetes or asthma and ensure ongoing,
appropriate care.
4:16:50 PM
SENATOR HUGHES noted that integrated medical homes, like the
Veterans Health Administration, allow coordinated care between
pharmacists and other providers. She expressed concern that
standalone pharmacies could lead patients to bypass their
physicians. She asked about potential delays and longer wait
times if pharmacists provide most direct care.
4:17:47 PM
MS. SEIGNNEMARTIN answered that not all pharmacies will offer
these services, as many lack the capacity. She said independent
or well-equipped pharmacies could provide this care, especially
where waiting times are manageable.
4:18:17 PM
SENATOR GIESSEL asked if she is aware of how many complaints
have been filed with the Board related to pharmacist practice.
4:18:38 PM
MS. SEIGNNEMARTIN replied no. She stated that the Idaho board's
experience with this practice model showed that implementing it
did not lead to an increase in complaints or investigations.
4:19:08 PM
CHAIR DUNBAR asked if Senator Giessel would like to direct the
question to Ms. Schaber.
SENATOR GIESSEL replied yes.
4:19:20 PM
MS. SCHABER responded that during her time on the board there
were no known investigations or complaints regarding pharmacists
practicing under collaborative agreements or their current
limited prescriptive authority.
4:19:47 PM
SENATOR CLAMAN referring to federal providers and non-federal
providers, in Alaska, he asked whether a veteran can receive a
prescription from a VA facility pharmacist, when in the
pharmacist's scope of practice, and whether non-veterans must
see a doctor or other provider for the same prescription.
4:20:22 PM
MS. SEIGNNEMARTIN answered yes.
4:21:20 PM
JENNIFER ADAMS, Associate Dean, L.S. Skaggs College of Pharmacy,
Idaho State University/University of Alaska Anchorage,
Pocatello, Idaho, testified by invitation on SB 147. She said
she is also a professor of pharmacy practice and teaches
pharmacy law in both Idaho and Alaska. She is therefore familiar
with statutes on pharmacy law in Alaska.
4:23:13 PM
MS. ADAMS stated that pharmacists across the U.S. receive
standardized education and training accredited by the
Accreditation Council for Pharmacy Education, including physical
assessment, diagnosis, and independent prescribing within their
scope of practice. She said states like Idaho have full-scope
authority for pharmacists, and experience there shows that
pharmacists provide safe, effective, and cost-efficient care
without incidents of practicing beyond their training. Services
have been introduced gradually to ensure safety, increase
access, and allow patients to receive timely care for minor
illnesses directly in pharmacies.
4:26:13 PM
MS. ADAMS said that pharmacies are increasingly providing
treatment for minor ailments such as pinkeye, uncomplicated
UTIs, and cold sores, allowing patients to receive timely care.
Some community pharmacies, especially in rural areas, have also
begun offering these services, though it remains limited outside
federal systems.
4:27:23 PM
MS. ADAMS shared a story of a patient that came to a pharmacist
for help. She said in a rural community, a pharmacist began
offering buprenorphine therapy after a patient approached the
pharmacy, explaining that he had been purchasing the medication
off the street because there were no local clinics providing
this service. Out of concern for the patient's safety, the
pharmacist undertook additional training and began providing
supervised treatment. She said as a result, the patient now
receives therapy every two weeks, is successfully staying clean,
has regained stability in his personal and professional life,
and is able to support his family. This pharmacy now serves over
30 patients, providing care they could not otherwise access. She
said this story highlights the importance of SB 147 in expanding
access to essential healthcare services, particularly for opioid
use disorder, while allowing pharmacists to practice at the top
of their education and training. Implementing SB 147 would help
modernize pharmacy practice in Alaska, enable ISU-UA graduates
to fully utilize their skills, and provide meaningful, life-
changing care within their communities.
4:31:02 PM
SENATOR HUGHES asked how SB 147 is more restrictive than Idaho's
statute.
MS. ADAMS replied that SB 147 places additional restrictions on
the types of services pharmacists can provide, focusing on
preventative care, minor, and self-limiting conditions. She said
Idaho allows pharmacists to have full-scope authority for
diagnosing and prescribing without such limits.
4:32:25 PM
SENATOR HUGHES stated that, "outcomes related to the cure or
prevention of a disease, elimination or reduction of a patient's
symptoms or resting or slowing of a disease process" seems
broad. She asked for examples of something that's outside the
scope.
4:32:45 PM
MS. ADAMS replied that pharmacists are limited by law and the
standard of care to conditions within their training, excluding
highly complex diagnoses. Pharmacists may manage common
conditions like diabetes or hypertension but not rare or
advanced diseases.
4:34:10 PM
SENATOR GIESSEL stated that she had a question related to the
fiscal note.
4:34:29 PM
SYLVAN ROBB, Director, Division of Corporations, Business, and
Professional Licensing, Department of Commerce, Community and
Economic Development (DCCED), Juneau, Alaska, answered questions
regarding SB 147.
4:34:38 PM
SENATOR GIESSEL noted that SB 147, page 2, has the unusual
inclusion of $30,000 in legal investigation costs starting in
FY26 and continuing annually. She asked why investigations and
complaints are assumed to occur immediately upon implementation
of SB 147.
4:35:35 PM
MS. ROBB replied that that the fiscal note reflects receipt-
supported authority, not a new $30,000 appropriation, and allows
spending if needed. With a significant scope-of-practice change,
the division anticipates increased legal questions and potential
complaints requiring Department of Law support. She said these
costs are expected to taper off overtime as issues are resolved
and the scope becomes settled.
4:36:58 PM
SENATOR GIESSEL asked why the $30,000 is listed under change of
revenues if it is expected to be covered by licensing fees. She
noted that under the current budget constraints the fiscal note
will not be supported by the legislature.
4:37:25 PM
MS. ROBB responded that all costs would be covered by licensing
fees. The fiscal note reflects a change in revenue because it
grants receipt authority to collect and spend additional
licensing receipts, not new general fund appropriations. She
said division fiscal notes always show revenues equal to
projected costs.
4:38:09 PM
CHAIR DUNBAR held SB 147 in committee.
SB 134-PHARMACY BENEFITS MANAGER;3RD PARTY ADMIN
4:38:24 PM
CHAIR DUNBAR announced the consideration of SENATE BILL NO. 134
"An Act relating to pharmacy benefits managers; relating to
third-party administrators; and providing for an effective
date."
4:39:12 PM
CHAIR DUNBAR solicited the will of the committee.
4:39:14 PM
SENATOR GIESSEL moved to report SB 134, work order 34-LS0461\A,
from committee with individual recommendations and attached
fiscal note(s).
4:39:29 PM
CHAIR DUNBAR found no objection and SB 134 was reported from the
Senate Health and Social Services Standing Committee.
4:39:54 PM
There being no further business to come before the committee,
Chair Dunbar adjourned the Senate Health and Social Services
Standing Committee meeting at 4:39 p.m.